[Ip-health] WHA73: Written statement of KEI - Agenda item 3 - Address by WHO Director-General devoted to the COVID-19 pandemic response in advance of the opening of the Health Assembly | Knowledge Ecology International
james.love at keionline.org
Sat May 16 10:31:02 PDT 2020
KEI is an accredited non-state actor at the World Health Organization
(WHO). This is our statement at the 73rd World Health Assembly.
Knowledge Ecology International
Meeting: Seventy-third World Health Assembly
Written statements on COVID-19 pandemic
The biggest question today is when will our health and economies be safe
from the coronavirus. Related are questions about fairness, and capacity to
supply everyone with a vaccine, drug or other technology to diagnose,
prevent or treat the virus.
There should be no monopolies on patents, regulatory exclusivities, data or
know-how in this pandemic. All relevant technology for COVID-19 products
should be available either free or openly licensed with non-discriminatory,
reasonable and affordable royalties.
Relevant technologies should become global public goods. Where incentives
are needed, they should be delinked from prices and exclusive rights.
Governments, particularly if working together, have massive power to ensure
technology to fight COVID-19 are open to all manufacturers, and cheap.
Governments control IP rights and are spending billions to fund R&D and buy
relevant products. Governments need to cooperate and use their power to
benefit the public.
The proposal by Costa Rica, the WHO, and others to create a global pool for
rights in inventions, data, biologic resources and know-how useful in the
prevention, detection and treatment of COVID-19 is important, needs to be
implemented with haste, and with full backing of every country and every
donor funding biomedical R&D.
The ACT initiative and institutions like CEPI must openly license all IP
and know-how, to scale up global production of relevant products.
The public wants transparency.
The WHO R&D Observatory needs to have a database of all R&D related to the
coronavirus, including information on the costs of trials, the funders and
the public sector subsidies. All research contracts and all licenses should
be public. The WHO needs to create a global database of prices for all
relevant COVID 19 drugs, vaccines and diagnostic tests.
James Love. Knowledge Ecology International
U.S. Mobile +1.202.361.3040
U.S. office phone +1.202.332.2670
More information about the Ip-health